Corbus Pharmaceuticals Holdings, Inc. 8-K

What Happened
Corbus Pharmaceuticals Holdings, Inc. announced on April 16, 2026 (filing date) that it entered into amended and restated employment agreements effective April 15, 2026 with CEO Yuval Cohen, Ph.D., and CFO Sean Moran. Each agreement is for a two‑year term expiring April 15, 2028 and sets base salary, bonus targets, equity award eligibility, non‑compete and non‑solicit restrictions, and severance/benefits provisions, including special terms if termination occurs around a change in control.

Key Details

• CEO Yuval Cohen: base salary $673,625; target annual bonus up to 60% of base salary; employment term through April 15, 2028.
• CFO Sean Moran: base salary $501,273; target annual bonus up to 40% of base salary; employment term through April 15, 2028.
• Severance if terminated without cause or for good reason (subject to release and covenant compliance): generally 12 months base salary for each executive (COBRA coverage reimbursement for 12 months); during a Change in Control Period severance increases to 24 months for Cohen and 18 months for Moran.
• Change‑in‑control protections: accelerated vesting of outstanding equity awards for Cohen (and for Moran per agreement), and enhanced bonus treatment (Cohen: current year bonus at 2x target; Moran: current year bonus at target).
• Both executives subject to 6‑month post‑termination non‑compete (enforced in connection with severance), 12‑month non‑solicit, confidentiality and assignment of inventions; severance may be reduced to avoid adverse tax outcomes under IRC §4999.
• Forms of the agreements are attached as exhibits to the 8‑K.

Why It Matters
These updated agreements formalize pay, incentives and severance for Corbus’s top two executives, which affects executive retention and the company’s potential cash and equity obligations if either executive departs or a change in control occurs. Investors should note the specific severance and change‑in‑control triggers (including accelerated equity vesting and bonus multipliers) because they can increase near‑term compensation expense or payouts in certain termination or transaction scenarios.